Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...
The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...
The Plain Dealer Cleveland on MSN13d
Are you at risk for age-related macular degeneration? Cleveland study suggests ancestry may hold cluesStudy from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular degeneration.
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback